SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project with an active developer, attracting attention from investors looking to move beyond typical pump-and-dump cycles. The community is actively pushing for mainstream platform visibility and increased trading volume to support their long-term goal of hitting significant market cap milestones.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum and trending as investors react to a strategic payroll infrastructure partnership with Stellar, fueling optimism for broader institutional adoption. The community is actively discussing the potential for future XRP collaboration and a possible Coinbase listing, with many using the current price consolidation as a strategic accumulation phase.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as investors highlight its ultra-low circulating supply and small market capitalization as key drivers for significant growth potential. The community is actively discussing the token's upside, with many calling for increased volume and exchange listings to catalyze a major breakout.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing heightened investor interest driven by a combination of its ongoing strategic pivot into pharmaceutical manufacturing, a fortified balance sheet, and market speculation regarding potential domestic supply chain contracts. Community discussion remains heavily focused on the company's turnaround progress, its status as a potential beneficiary of new pharmaceutical import tariffs, and bullish long-term value projections based on its infrastructure and asset base.

Grace Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

Grace Therapeutics Inc.

Grace Therapeutics is gaining momentum as investors anticipate the upcoming PDUFA date for its drug candidate GTx-104. The community is focused on the potential for institutional accumulation and the stock's low float, with many discussing the strategic value of the asset as the company nears its regulatory catalyst.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened social media activity and trading volume driven by investor interest in its post-quantum cryptography features and recent institutional developments, including a shift toward US-based operations. The community remains deeply divided, with long-term holders expressing conviction in the project's technology and future adoption, while active traders continue to debate its recent price volatility and past performance relative to broader market trends.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics is attracting significant attention as investors track its Phase 2 LOTUS trial progress and potential for its lead asset, AVTX-009, to impact the competitive immunology market. The community is actively discussing recent analyst coverage, including buy ratings and optimistic price targets, while maintaining a cautious dialogue regarding the company's long-term financing needs and historical volatility.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is currently drawing significant attention as investors shift toward defensive, high-quality dividend compounders amid broader market volatility. The community is actively debating whether the stock's current price levels represent a strategic accumulation point for long-term wealth building or a potential value trap as the company navigates ongoing cost-savings initiatives.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and active call buying as the community debates potential short-squeeze dynamics and the impact of a high short interest against an anticipated operational turnaround. Traders are closely monitoring the stock's price action around critical technical levels, fueled by speculation regarding activist interest and upcoming earnings, while opinions remain sharply divided on the company's long-term sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Coinbase, on Thursday, received conditional approval from the OCC to establish Coinbase National Trust Company.</li><li>The company said the trust charter is intended to bring federal regulatory oversight to Coinbase’s custody and market infrastructure services.</li><li>Conditional approval requires Coinbase to complete governance, staffing, and operational readiness steps before launch.</li></ul>Coinbase (COIN) announced on Thursday that it has received conditional approval from the Office of the Comptroller of the Currency (OCC) to charter Coinbase National Trust Company. With the approval, Coinbase joins Circle (CRCL), Ripple (XRP), and Paxos, which received conditional trust bank charters back in December.The company said that the approval does not signal a shift into traditional banking. “Coinbase is not becoming a commercial bank. We will not be taking retail deposits. We will not be engaging in fractional reserve banking,” it&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.coinbase.com/en-in/blog/coinbase-receives-conditional-occ-approval-building-the-future-of-finance">said</a> in a blog post. It explained that the trust charter is intended to formalize its custody and infrastructure operations under a unified federal framework.<a href="https://stocktwits.com/symbol/COIN">COIN’s stock</a> edged 0.72% lower in afternoon trade amid weakness in the broader markets, both cryptocurrency and equities. On Stocktwits, retail sentiment around the cryptocurrency exchange remained in ‘bearish’ territory over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_02_133038_png_30719e7580.webp" alt="Screenshot 2026-04-02 133038.png" width="1275" height="145"><figcaption>COIN retail sentiment and message volume on April 2 as of 1:30 p.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">What Conditional OCC Approval Means For Coinbase</h2>Conditional approval from the OCC means that a company’s application is acceptable in principle but still subject to additional requirements before it can begin operations.For Coinbase, this means completing several steps, including establishing a board, finalizing governance structures, and passing a pre-opening regulatory examination. Only after these conditions are met can Coinbase National Trust Company begin operating as a national trust bank.The debate over whether companies like Coinbase will be allowed to offer rewards on stablecoin deposits continues to unfold in Washington. Crypto firms are&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/new-clarity-act-stablecoin-rules-set-for-crypto-review-today-banks-next/cZ7xDkORI8K">reportedly</a> scheduled to review a new draft of the stablecoin yield proposal today in a close-door session on Thursday, followed by the banking industry on Friday.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-67-after-oil-spikes-trump-iran-warning-rattles-risk-assets/cZ7xFXXRI8G">Bitcoin Falls Below $67,000 After Oil Spikes, Trump's Iran Warning Rattles Risk Assets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monitors display Coinbase signage during the company's initial public offering (IPO) at the Nasdaq market site April 14, 2021 in New York City. 

Coinbase Joins Circle, Ripple, Paxos In US Crypto Trust Bank Cohort After OCC Conditional Approval 

Coinbase said it will not take retail deposits or operate as a commercial bank.

Cryptocurrency

Coinbase said it will not take retail deposits or operate as a commercial bank.


Zacks Investment Ideas feature highlights Ark Invest's, SK Telecom, NVIDIA, Nebius and Sandisk 

Ark Invest's, SK Telecom, NVIDIA, Nebius and Sandisk have been highlighted in this Investment Ideas article.


<ul class="summary-bullets"><li>The therapy also demonstrated encouraging efficacy with changes that resulted in improved laboratory markers for the disease and the resolution of anemia, the company said.&nbsp;</li><li>Beam is now looking to make an application seeking the U.S. Food and Drug Administration’s approval for the therapy as early as 2026 year-end.</li></ul>Shares of Beam Therapeutics (BEAM) rallied 3% after hours on Wednesday after the company said that its clinical trial evaluating ristoglogene autogetemcel for the treatment of sickle cell disease (SCD) with severe vaso-occlusive crises demonstrated encouraging efficacy.The company said that risto-cel, its investigational genetically modified cell therapy, demonstrated an acceptable safety profile and encouraging efficacy with changes that resulted in improved laboratory markers for the disease and the resolution of anemia. The data from the trial was published in the The New England Journal of Medicine.Sickle cell disease (SCD) is a group of inherited blood disorders caused by a genetic mutation leading to abnormal hemoglobin, which causes red blood cells to become rigid, sickle-shaped, and prone to breaking down. SCD with severe vaso-occlusive crises (VOC) involves sickle-shaped red blood cells blocking blood flow, causing intense, often bone-deep pain, ischemia, and organ damage.“Based on the totality of data generated to date from the BEACON study and the optimized treatment and manufacturing process, we believe risto-cel has the potential to be best-in-class. With an estimated 10,000 patients with SCD in the U.S. eligible for gene therapies, and significant demand expected as these treatments become more widely available, risto-cel is well positioned within this growing market,” said Amy Simon, chief medical officer of Beam.Beam is now looking to make an application seeking the U.S. Food and Drug Administration’s approval for the therapy as early as 2026 year-end. The FDA previously granted risto-cel orphan drug designation and Regenerative Medicine Advanced Therapy (RMAT) designation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around BEAM stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from high to normal levels.<a href="https://stocktwits.com/symbol/BEAM">BEAM stock</a> has gained 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-agpu-stock-rise-today/cZ7HyVtRIF0">Why Did AGPU Stock Rise 120% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Beam Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is BEAM Stock Edging Higher After Hours Today?

The company said that risto-cel, its investigational genetically modified cell therapy, demonstrated an acceptable safety profile in a trial. 

Equity

OpenAI & Anthropic Prove the AI Revolution is Just Starting

While geopolitical tensions provide a constant drumbeat of anxiety for the average investor, the underlying fundamentals of the AI sector tell a much different story. 

<ul class="summary-bullets"><li>OpenAI on Tuesday announced that it raised $122 billion in equity financing – the largest investment round for any company.</li><li>The financing and stake sale of individual investors comes ahead of a potential initial public offerings, expected towards the end of the year.</li><li>Investors are increasingly eying exposure to marquee pre-IPO tech companies such as SpaceX and Anthropic, investing into funds that own them.</li></ul>Noted tech investor Cathie Wood has poured in $240 million as part of OpenAI’s mammoth $122 billion funding round – a significant development that opens the door for retail investors to gain exposure to the world’s leading AI company, which is also gearing up for an initial public offering.The investment is made from her three exchange traded funds ARK Innovation (ARKK), ARK Fintech Innovation (ARKF) and ARK Next Generation Internet (ARKW), according to ARK Invest disclosures.&nbsp;As a percentage of their total holdings, the OpenAI stake accounts for 3.1% for ARKK, and 3.0% for ARKW and ARKF. Wood had earlier invested a similar amount in OpenAI through her venture fund, the ARK Venture Fund.Separately, OpenAI said it secured over $3 billion investment as part of the round from individual investors – a first for the company.&nbsp;OpenAI is “broadening ownership and giving more people the opportunity to share in the upside economics of OpenAI and the AI era,” it said in the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://openai.com/index/accelerating-the-next-phase-ai/">blog post</a> announcing its fundraise on Tuesday.Although the ARK ETFs have declined in the recent months, with ARK Innovation ETF (ARKK) logged its worst quarter since early 2025, the OpenAI stake might increase their appeal.Investors are increasingly seeking exposure to marquee pre-IPO tech companies such as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/how-to-buy-spacex-before-ipo-5-funds-owning-spacex/cZ3uVbqRIlL">SpaceX</a> and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anthropic-s-ipo-said-to-be-coming-as-early-as-october-here-s-how-to-pick-up-a-stake-before-it-goes-public/cZ3uU4aRIlA">Anthropic</a>, and are investing in funds that own them, Stocktwits has reported.&nbsp;Besides the ARK ETFs, KraneShares Artificial Intelligence &amp; Technology ETF (AGIX), Fundrise Innovation Fund (VCX), and Destiny Tech100 (DXYZ) are some of the funds that have seen significant interest among retail traders on Stocktwits of late.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-stock-tumbles-toward-9-year-low-retail-traders-shrug-off-soft-outlook/cZ7HhpHRInK">Nike Stock Tumbles Toward 9-Year Low: Retail Traders Shrug Off Soft Outlook To Scoop Up ‘Crazy Good Pricing’</a>

Cathie Wood, CEO & Chief Investment Officer of ARK Invest, speaks onstage during Day 2 of 2023 Invest Fest at Georgia World Congress Center on August 27, 2023 in Atlanta, Georgia. (Photo by Paras Griffin/Getty Images)

Cathie Wood Makes $240M Bet In OpenAI's Mammoth Fundraise As IPO Looms

OpenAI said it is broadening access to its equity to public investors through the ARK ETFs – and also separately raised $3 billion from individual investors.

Cathie Wood, Founder & CEO, Ark Invest, speaks during the second day of the FII PRIORITY Summit held at the Faena Hotel on February 20, 2025 in Miami Beach, Florida. (Photo by Joe Raedle/Getty Images)

Cathie Wood’s Flagship Ark Fund Just Logged Its Worst Quarter In Over A Year — One Mega-Cap Stock Is Largely To Blame

Since early 2025, Tesla has shifted focus from EVs toward robotaxis, Full Self-Driving (FSD) rollout, Cybercab production, and AI-driven robotics.

<ul class="summary-bullets"><li>Bitmine has completed over 78% of its goal to acquire 5% of Ethereum’s total supply.</li><li>The company added around 71,179 ETH in the past week, bringing total holdings to around 4.7 million ETH.</li><li>Chairman Tom Lee said the crypto market is nearing the end of a “mini-crypto winter” and highlighted oil prices as a key driver.</li></ul>Shares of Bitmine Immersion Technologies (BMNR) rose nearly 5% in pre-market trade on Monday after the company announced that its treasury now holds 3.92% of Ethereum’s (ETH) overall token supply.Bitmine Chairman Tom Lee&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bmnr-stock-gains-after-bitmine-biggest-ethereum-buy-this-year/cZ3mfarRI0L">reiterated</a> that the crypto market is at the tail-end of the current “mini-crypto winter” and that tokens are a “good wartime store of value.”&nbsp;"The inverse correlation of crypto (and equities) to oil has been increasing and is at the highest levels in the past year. This is logical,” he said. “Until equity markets become comfortable with the future trajectory of oil prices, rising oil is a headwind for equities and crypto. And in a sense, the crypto winter likely ends when the upside risk to oil prices peaks.”The company said it has now completed over 78% of its goal of acquiring 5% of Ethereum’s circulating supply. Bitmine has continued its trend of increasing ETH purchases week-on-week, accumulating around 71,179 ETH in the past week, bringing its total to around 4.7 million ETH.<h2 class="st-heading-2">BMNR Stock Rises, Ethereum Recaptures $2,000</h2>Shares of Bitmine rose alongside Ethereum as it reclaimed the $2,000 mark on Monday morning amid a&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-recovers-from-65-000-analysts-warn-rally-may-be-short-lived/cZERZEoRIZp">broader rally</a> in the cryptocurrency market.&nbsp;<a href="https://stocktwits.com/symbol/BMNR/">BMNR’s stock</a> rose 4.3% in early morning trade, while retail sentiment on Stocktwits around the company fell to ‘neutral’ from ‘bullish’ territory over the past day, and chatter remained at ‘low’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_30_093808_png_c18a6a665e.webp" alt="Screenshot 2026-03-30 093808.png" width="1235" height="142"><figcaption>BMNR retail sentiment and message volume on March 30 as of 9:20 a.m. ET | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/coins/ethereum">Ethereum’s price</a> also rose around 4.3% in the last 24 hours to around $2,070. Retail sentiment around the leading altcoin on Stocktwits remained in ‘bearish’ territory amid ‘normal’ levels of chatter.Bitmine said its balance sheet is now worth $10.7 billion, which includes 197 Bitcoin (BTC), a $200 million stake in Beast Industries, a $102 million stake in Eightco Holdings (ORBS), and total cash of $961 million, in addition to its Ethereum holdings.&nbsp;Last week, the company also&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/tom-lee-says-mavan-will-be-largest-ethereum-staking-platform/cZ3YpSZRIS1">announced</a> the launch of its Made in America Validator Network (MAVAN) with Lee stating that it will be the “largest Ethereum staking network in the world.”Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-recovers-from-65-000-analysts-warn-rally-may-be-short-lived/cZERZEoRIZp">Bitcoin Recovers From $65,000 – Analysts Warn Rally May Be Short-Lived</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BMNR’s Tom Lee Says Crypto Winter May End When Oil Risk Peaks – Bitmine Adds Over 70,000 ETH To Holdings

Bitmine Immersion Technologies’ Ethereum holdings now total over 4.7 million ETH, amounting to nearly 4% of the altcoin’s supply.

The Zacks Analyst Blog Highlights FWD, ARKK, CHAT, AIQ and VOO

ARK Innovation ETF and peers offer exposure to AI-driven disruption, as investors are urged to stay invested despite market volatility and geopolitical risks.

<ul class="summary-bullets"><li>Cathie Wood’s ARK Investment Management bought more Tempus shares this week, even as the stock hit a one-year low and the firm trimmed exposure across several large tech holdings.</li><li>So far this year, ARKK and ARKG have poured nearly $28 million into Tempus shares.</li><li>The buying followed expanding AI-driven oncology partnerships with Daiichi Sankyo, Merck, Blood Cancer United, NYU Langone Health and Northwestern Medicine.</li></ul>Shares of Tempus AI Inc. (TEM) drew renewed attention this week after Cathie Wood’s ARK Investment Management added to its position while cutting stakes across several large tech firms, signaling continued conviction even as the stock hit a one-year low.<a href="https://stocktwits.com/symbol/TEM">TEM stock</a> fell nearly 3% on Thursday and is headed for its fifth straight weekly loss, shedding roughly 25% over the past five weeks.<h2 class="st-heading-2">Tempus Only Stock ARKK Bought In Latest Buy</h2>On Thursday, ARK Investment Management purchased 51,881 shares through the ARK Innovation ETF (ARKK), worth $2.4 million based on Tempus’ closing price of $45.53. Notably, Tempus was the only stock ARKK bought in the session, even as the firm reduced exposure across several large tech holdings, including Alphabet, Baidu, Broadcom, Illumina, Archer Aviation, AMD, Nvidia and Meta.The purchase followed additional accumulation a day earlier, when ARKK acquired 72,290 shares and the ARK Genomic Revolution ETF (ARKG) added 12,649 shares, worth $4 million.Earlier in the quarter, ARK accumulated shares following Tempus’ earnings report and momentum from its partnerships. On Feb.25, ARKK bought 179,013 shares, while ARKG added 33,812 shares, implying purchases worth about $11.4 million.The accumulation this year began on Feb.12, when ARKK purchased 174,585 shares and ARKG added 35,716 shares, representing roughly $10.7 million using Tempus’ $50.78 closing price. Cumulatively, ARK poured nearly $28 million into Tempus shares so far this year.<h2 class="st-heading-2">Tempus Expands Big Pharma AI Deals</h2>ARK’s accumulation comes after Tempus expanded its role in precision oncology research and clinical-trial optimization pipelines. Most recently, Tempus partnered with Japanese pharma giant Daiichi Sankyo to develop a new cancer therapy, using its Prism2 AI model to better identify patients most likely to benefit from treatment.Earlier this month, the company expanded its collaboration with Merck to support biomarker discovery across oncology and potentially broader therapeutic programs using its Lens platform and real-world datasets. Tempus also announced a deal with Blood Cancer United to build a registry focused on pediatric acute myeloid leukemia (AML).The developments followed additional collaborations this year with Median Technologies, NYU Langone Health and Northwestern Medicine supporting genomic testing workflows, lung-cancer screening and molecular oncology programs.<h2 class="st-heading-2">Wall Street Sees Long-Term Upside For Tempus</h2>Wall Street commentary this year reflected some price-target resets following quarterly results, but maintained confidence in Tempus’ long-term platform strategy. H.C. Wainwright raised its target to $95 and maintained a 'Buy' rating, while Baird lifted its target to $68 and reiterated an 'Outperform' rating. BTIG also maintained a 'Buy' rating, citing Tempus’s “first mover advantage on its large data business” and $1.1 billion backlog supporting expansion.Meanwhile, JPMorgan lowered its price target to $60 and kept a 'Neutral' rating, citing “clouded visibility” around data-segment upside, while TD Cowen cut its target to $70 and maintained a 'Hold' rating. Mizuho initiated coverage with an 'Outperform' rating and a $100 target, calling precision oncology diagnostics a $40 billion market growing about 30% annually.Tempus reported fourth-quarter revenue of $367.2 million, beating estimates, and projected fiscal-year 2026 revenue of about $1.59 billion, roughly in line with forecasts. CEO Eric Lefkofsky said that growth in diagnostics volumes and the company’s AI-driven data platform is expected to support expansion in the coming years.<h2 class="st-heading-2">What Do Retail Traders Feel About Tempus AI?</h2>On Stocktwits, retail sentiment for TEM has been in the ‘bearish’ territory over the past week, slipping from ‘extremely bullish’ levels a month ago amid over a 90% surge in message volumes this quarter. Meanwhile, the stock has seen nearly a 50% jump in watchers over the past year.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/tem_ss_png_ca8662c8d0.webp" alt="tem ss.png" width="978" height="143"><figcaption>TSLA sentiment and message volume as of March 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/GoAt2OG/message/648701463">expressed</a> optimism, noting that “The only thing Cathie bought today was us here at Tempus.”<stembedurl>https://stocktwits.com/GoAt2OG/message/648701463</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/MihaiGG/message/648612357">said</a>, “Experience told me that this is a good moment to buy, with what we can or what we have. Cathie is loading up, so, [why] don’t we? It will boom, someday, but success needs pain.”<stembedurl>https://stocktwits.com/MihaiGG/message/648612357</stembedurl>TEM stock has declined 15% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-misses-gas-price-tailwind-ahead-of-q1-delivery-report/cZ3uFS9RIli">Tesla Stock Fails To Catch Tailwind From Surging Gas Prices Ahead Of Crucial Q1 Delivery Report</a>

In this photo illustration logo of Tempus AI is seen on a smartphone against a screen displaying a trade markets illustration on April 15, 2024 in Krakow, Poland. (Photo by Dominika Zarzycka/NurPhoto via Getty Images)

Tempus AI Stock Near 1-Year Low: Cathie Wood’s ARK Buys More While Offloading Nvidia, Meta, Other Tech Plays

Tempus AI was the only stock purchased by ARK Innovation ETF (ARKK) in the latest session, signaling targeted conviction.

Stay Invested Despite Market Chaos With These ETFs

Stay invested amid market chaos. AI disruption and geopolitics may drive volatility, but these ETFs offer long-term growth and stability.

ARK ETF Trust - ARK Innovation ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

ARKK
ARK Innovation ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ARKK News

ARKKARK Innovation ETF